SLS: SELLAS Life Sciences Group, Inc. Common Stock
Company identity verified 2026-11-09. Current quotes, news, filings and options load in the terminal; unavailable data is left unavailable.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
| Primary exchange (MIC) | XNAS |
|---|---|
| Listed since | 2008-03-12 |
| Market capitalization | $1.6 billion |
| Shares outstanding | 201,945,709 |
| Employees | 13 |
| Headquarters | NEW YORK, NY, US |
| Website | www.sellaslifesciences.com |
SLS has traded between $7.54 and $9.00 in the current session, a range of $1.46. The latest price of $7.84 sits in the middle of that range (21% of the way from low to high). It opened at $8.34, a gap up of 3.86% from the prior close of $8.03. The volume-weighted average price is $8.36, and the stock is trading below it. Traders often use VWAP as a gauge of whether buyers or sellers have had the better average entry today.
| Open | $8.34 |
|---|---|
| High | $9.00 |
| Low | $7.54 |
| Previous close | $8.03 |
| Volume | 11,201,572 |
| VWAP | $8.36 |
StockMarketLoop's Market Position model estimates how the shares traded between 2026-08-16 and 2026-11-14 were bought. Its estimate of the average cost basis is $10.70; at $7.84 the stock trades 26.7% below that level. About 3.8% of those shares are estimated to be held at a profit at the current price. A low figure means most recent buyers are underwater, so rallies can meet selling from holders trying to get back to break even. The densest nearby clusters of cost basis sit around $7.78 (support) and $11.48 (resistance). Roughly 70% of the estimated cost basis lies between $8.42 and $12.40, and 90% between $7.85 and $14.11.
This is a model estimate built from price and volume history, not a record of actual positions.
Quote figures come from StockMarketLoop's market data feed and may be delayed; the timestamp in the summary above shows when they were observed. Company details come from public reference data. The cost-basis section is a statistical model, not a forecast. Nothing here is investment advice; see our financial disclaimer and editorial policy.
Company identity verified 2026-11-09. Current quotes, news, filings and options load in the terminal; unavailable data is left unavailable.